Article PDF
References
Geraghty J. Adenomatous polyposis coli and translational medicine. Lancet, 1996, 348: 422
Marincola F M. Translational medicine: A two-way road. J Transl Med, 2003, 1: 1
Zerhouni E A. Translational and clinical science—time for a new vision. N Engl J Med, 2005, 353: 1621–1623
Zerhouni E. Medicine. The NIH Roadmap. Science, 2003, 302: 63–72
Fox C S, Evans J C, Larson M G, et al. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation, 2004, 110: 522–527
Dawber T R, Meadors G F, Moore F E Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health, 1951, 41: 279–281
Kannel W B, Feinleib M, McNamara P M, et al. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol, 1979, 110: 281–290
Splansky G L, Corey D, Yang Q, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol, 2007, 165: 1328–1335
Castelli W P. Epidemiology of coronary heart disease: the Framingham study. Am J Med, 1984, 76: 4–12
Wilson P W, D’Agostino R B, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation, 1998, 97: 1837–1847
Gordon T, Kannel W B, Hjortland M C, et al. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med, 1978, 89: 157–161
Wilson P W, Castelli W P, Kannel W B. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol, 1987, 59: 91G–94G
O’Donnell C J, Cupples L A, D’Agostino R B, et al. Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study. BMC Med Genet, 2007, 8: S4
Larson M G, Atwood L D, Benjamin E J, et al. Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet, 2007, 8: S5
Kannel W B, Dawber T R, Kagan A, et al. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med, 1961, 55: 33–50
Tobert J A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov, 2003, 2: 517–526
Kannel W B. Clinical misconceptions dispelled by epidemiological research. Circulation, 1995, 92: 3350–3360
Steinberg D, Avigan J, Feigelson E B. Effects of triparanol (Mer-29) on cholesterol biosynthesis and on blood sterol levels in man. J Clin Invest, 1961, 40: 884–893
Kirby T J. Cataracts produced by triparanol. (MER-29). Trans Am Ophthalmol Soc, 1967, 65: 494–543
Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res, 1992, 33: 1569–1582
Alberts A W, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA, 1980, 77: 3957–3961
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344: 1383–1389
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998, 339: 1349–1357
Sacks F M, Pfeffer M A, Moye L A, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996, 335: 1001–1009
Meier B, Bachmann D, Luscher T. 25 years of coronary angioplasty: almost a fairy tale. Lancet, 2003, 361: 527
The world health report. 2004
Report on cardivascular disease in China. 2010
Guarente L, Picard F. Calorie restriction—the SIR2 connection. Cell, 2005, 120: 473–482
Koubova J, Guarente L. How does calorie restriction work? Genes Dev, 2003, 17: 313–321
Colman R J, Anderson R M, Johnson S C, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science, 2009, 325: 201–204
Fontana L, Meyer T E, Klein S, et al. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA, 2004, 101: 6659–6663
Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol, 2005, 6: 298–305
Canto C, Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab, 2009, 20: 325–331
Zhang Q J, Wang Z, Chen H Z, et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res, 2008, 80: 191–199
Zhou S, Chen H Z, Wan Y Z, et al. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res, 2011, 109: 639–648
Zhang R, Chen H Z, Liu J J, et al. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem, 2010, 285: 7097–7110
Sokrates Stein S, Lohmann C, Schäfer N, et al. STRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J, 2010, 31: 2301–2309
Li L, Zhang H N, Chen H Z, et al. SIRT1 acts as a modulator of neointima formation following vascular injury in mice. Circ Res, 2011, 108: 1180–1189
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Zhang, Z., Chen, H. & Liu, D. Translational research: Lessons from past research, growing up nowadays, and development goal in future. Sci. China Life Sci. 54, 1085–1088 (2011). https://doi.org/10.1007/s11427-011-4252-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-011-4252-0